Adalimumab (Humira)

Handbook of Therapeutic Antibodies

Volumn 3, Issue , 2008, Pages 696-732

  Kupper, Hartmut ^a   Salfeld, Jochen ^b   Tracey, Daniel ^b   Kalden, Joachim R ^c  

^a ABBOTT GMBH AND CO KG   (Germany)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adalimumab; Immunogenicity; Methotrexate; Pharmacology; Tumor

Indexed keywords

EID: 84889478757     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch27     Document Type: Chapter

References (93)

1. Adalimumab [PI; prescribing information] (2006) North Chicago, IL: Abbott Laboratories.
2. Adalimumab [SPC; summary of product characteristics] (2006) Queenborough, UK: Abbott Laboratories. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/humira/humira.htm. Accessed September 12, 2006.
3. Anderson, P.J. (2005)Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.Semin Arthritis Rheum 34 (5 SUPPL.1): 19-22.
4. Baert, F., Noman, M., Vermeire, S., et al. (2003).Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
5. Bansback, N., Brennan, A., and Anis, A.H. (2005).A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Rev Pharmacoeconomics Outcomes Res 5: 519-529.
6. Barrera, P., Joosten, L.A., den Broeder, A.A., et al. (2001).Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis. Ann Rheum Dis 60: 660-669.
7. Barthel, H.R., Gille, T., Halbsguth, A., Kramer, M. (2005).Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 20: 1464-1465.
8. Bombardieri, S., Moutsopoulos, H.M., McKenna, F., Michel, B., Webber, D.G., Kupper, H. (2004)Rapid response to adalimumab after first dose: the ReAct trial [abstract]. Ann Rheum Dis 63(SUPPL.1): 261.
9. Bombardieri, S., Tzioufas, A.G., McKenna, F., et al. (2005)Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life clinical settings. Arthritis Rheum 52(SUPPL.): S144.
10. Bombardieri, S., McKenna, F., Drosos, A., et al. (2006)Efficacy and safety of adalimumab (HUMIRA) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice [abstract].Ann Rheum Dis 65(SUPPL. II): 178.
11. Braegger, C.P., Nicholls, S., Murch, S.H., Stephens, S., MacDonald, T.T. (1992).Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89-91.
12. Braun, J., Bollow, M., Neure, L., et al. (1995).Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38: 499-505.
13. Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., et al. (2005)The efficacy and safety of adalimumab (Humir) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis: 1-and 2-year results of the PREMIER study [abstract].Ann Rheum Dis 64(Suppl.III): 60.
14. Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., et al. for the PREMIER investigators (2006).The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37.
15. Burmester, G.R., van de Putte, L.B.A., Rau, R., et al. (2003).Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refractory RA. Ann Rheum Dis 62(Suppl.1): 192-193.
16. Burmester, G.R., Monteagudo Sáez, I., Malaise, M.G., Canas de Silva, J., Webber, D.G., Kupper, H. (2004)Efficacy and safety of adalimumab (Humir) in European clinical practices: the ReAct trial [abstract].Ann Rheum Dis 63(SUPPL.1): 266.
17. Burmester, G.R., Monteagudo Sáez, I., Malaise, M.G., Kary, S., Kupper, H. (2005)Adalimumab (Humir) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-yearresults of the ReAct study [abstract].Arthritis Rheum 52(SUPPL.): S541-S542.
18. Burmester, G.R., Monteagudo Sáez, I., Malaise, M.G., et al (2005).Adalimumab (Humir) is effective in patients who have previously been treated with TNFantagonists (etanercept and/or inflixima) in widespread clinical practice: 12-week outcomes in the REACT Trial. Ann Rheum Dis 64(Suppl.III): 423-424.
19. Catrina, A.I., Trollmo, C., Klint, E., et al. (2005).Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52: 61-72.
20. Cooper, W.O., Fava, R.A., Gates, C.A., Cremer, M.A., Townes, A.S. (1992).Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 89: 244-250.
21. den Broeder, A.A., van de Putte, L.B.A., Rau, R., et al. (2002).A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-αantibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29: 2288-2298.
22. den Broeder, A.A., Joosten, L.A., Saxne, T., et al. (2002).Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61: 311-318.
23. Emery, P., Schiff, M.H., Kalden, J.R., et al. (2004)Adalimumab (HUMIRA) plus methotrexate induces sustained remission in both early and long-standing rheumatoid arthritis. Arthritis Rheum 50(SUPPL.): S183-S184.
24. Furst, D.E., Schiff, M.H., Fleischmann, R.M., et al. (2003).Efficacy and safety of the fully human anti-tumour necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). JRheumatol 30: 2563-2571.
25. Georgopoulos, S., Plows, D., Kollias, G. (1996).Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46: 86-97.
26. Granneman, R.G., Zhang, Y., Noetersheuser, P.A., et al. (2003)Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humira, Abbott) in rheumatoid arthritis patients during Phase II/III clinical trials [abstract]. Arthritis Rheum 48 (SUPPL.): S140.
27. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., et al. (2006).Human anti-tumor necrosis factor monoclonal antibody (adalimuma) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 130: 323-333.
28. Heinzlef, O., Alamowitch, S., Sazdovitch, V., et al. (2000).Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 101: 36-40.
29. Jerne, N.K. (1974)Towards a network theory of the immune system. Ann d'Immunologie 125C: 373-389.
30. Kavanaugh, A., Grenwald, M., Zizic, T., et al. (2002)Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract]. Arthritis Rheum 45(SUPPL.9): S132.
31. Kavanaugh, A., Cush, J.J., Matteson, E. ACR Hotline (2003)FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II. CHF, infection, and other safety issues. Available at: http://www.rheumatology.org/publications/hotline/0803chf.asp?aud=mem. Accessed September 11, 2006.
32. Kaymakcalan, Z., Beam, C., Kamen, R., Salfeld, J. (2002)Comparison of adalimumab (D2E7), infliximab, and etanercept in the prevention of polyarthritis in a transgenic murine model of rheumatoid arthritis. Arthritis Rheum 46(SUPPL.): S304.
33. Keystone, E.D., Kavanaugh, A.F., Sharp, J.T., et al. (2004).Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 50: 1400-1411.
34. Keystone, E.D., Kavanaugh, A.F., Perez, J.L., Spencer-Green, G.T. (2004)Adalimumab (Humir) plus methotrexate provides sustained improvements in physical function over 2 years in treatment of patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 64(SUPPL.1): 278.
35. Keystone, E., Kavanaugh, A., Perez, J., Spencer-Green, G. (2004)Adalimumab (Humir) plus methotrexate provides sustained improvements in physical function over 2 years of treatment in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 63(SUPPL.1): 278.
36. Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., et al. (2005)Inhibition of radiographic disease progression in patients with longstanding rheumatoid arthritis following 3years of treatment with adalimumab (Humir) plus methotrexate [abstract]. Ann Rheum Dis 64(SUPPL.III): 419.
37. Kristensen, L., Saxne, T., Geborek, P. (2004)Adherence to therapy of infliximab, etanercept, adalimumab, and anakinra in chronic arthritis patients treated in clinical practice in southern Sweden [abstract]. Ann Rheum Dis 64(SUPPL.1): 263.
38. Landewé, R., Boers, M., Verhoeven, A., et al. (2002).COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46: 347-356.
39. Langley, R., Leonardi, C., Toth, D., et al. (2005)Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. J Am Acad Dermatol 52(3 SUPPL.): 203.
40. Lee, D.M. and Weinblatt, M.E. (2001).Rheumatoid arthritis. Lancet 358: 903-911.
41. Lee, S.J. and Kavanaugh, A. (2005).Adalimumab for the treatment of rheumatoid arthritis. Therapy 2: 13-21.
42. Lovell, D.J., Ruperto, N., Goodman, S., et al. (2004).Preliminary data from the Study of Adalimumab in Children with Juvenile Idiopathic Arthritis (JIA). Arthritis Rheum 50(Suppl.): S436-S437.
43. Magnano, M., Robinson, W.H., Genovese, M.C. (2004).Demyelination and the use of TNF inhibition. Clin Exp Rheumatol 22(5 Suppl.35): S134-S140.
44. Maini, R.N. and Taylor, P.C. (2000).Anticytokine therapy for rheumatoid arthritis. Annu Rev Med 51: 207-229.
45. Maini, R.N., Breedveld, F.C., Kalden, J.R., et al. (1998).Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563.
46. McGonagle, D., Conaghan, P.G., O'Connor, P., et al. (1999).The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Ann Rheum Dis 42: 1706-1711.
47. McQueen, F.M., Stewart, N., Crabbe, J., et al. (1998).Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 57: 350-356.
48. Mease, P.J. (2002).Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61: 298-304.
49. Mease, P. and Goffe, B.S. (2005).Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52: 1-19.
50. Mease, P.J., Gladman, D.D., Ritchlin, C.T., et al. for the ADEPT Study Group (2005).Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. ADEPT. Arthritis Rheum 52: 3279-3289.
51. Mease, P.J., Gladman, D.D., Ritchlin, C.T., et al. (2005)Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT [abstract]. Arthritis Rheum 52(SUPPL.): S215.
52. Mease, P., Sharp, J., Ory, P., et al. (2005)Inhibition of joint destruction in PsA with adalimumab: 48-week results of ADEPT [abstract]. Arthritis Rheum 52(SUPPL.): S631.
53. Mitoma, H., Horiuchi, T., Hatta, N., et al. (2005).Infliximab induces potent antiinflammatory responses by outside-toinside signals through transmembrane TNF-[945]. Gastroenterology 128: 376-392.
54. Möttönen, T., Hannonen, P., Korpela, M., et al. (2002).Delay to institution of therapy and induction of remission using singledrug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46: 894-898.
55. Murch, S.H., Lamkin, V.A., Savage, M.O., Walker-Smith, J.A., MacDonald, T.T. (1991).Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32: 913-917.
56. Murch, S.H., Braegger, C.P., Walker-Smith, J.A., MacDonald, T.T. (1993).Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709.
57. Nikas, S.N., Voulgari, P.V., Alamanos, Y., et al. (2006).Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 65: 257-260.
58. Papadakis, K.A., Shaye, O.A., Vasiliauskas, E.A., et al. (2005).Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75-79.
59. Partsch, G., Steiner, G., Leeb, B.F., Dunky, A., Broll, H., Smolen, J.S. (1997).Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24: 518-523.
60. Rau, R. (2002).Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(Suppl. III): ii70-ii73.
61. Ritchlin, C., Haas-Smith, S.A., Hicks, D., Cappuccio, J., Osterland, C.K., Looney, R.J. (1998).Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544-1552.
62. Salfeld, J., Kaymakcalan, Z., Tracey, D., Robert, A., Kamen, R. (1998)Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 41(SUPPL.): S57.
63. Sandborn, W.J., Hanauer, S., Loftus, E.V. Jr., et al. (2004).An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989.
64. Sandborn, W., Hanauer, S., Lukas, M., et al. (2005).Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-α monoclonal antibody adalimumab (Humir). Gastroenterology 128(4 Suppl.2): A-111.
65. Sandborn, W.J., Hanauer, S., Lukas, M., et al. (2005)Clinical remission and response in patients with Crohn's disease treated with open-label for 1 year with fully human anti-TNF-α monoclonal antibody adalimumab. Gut 54(SUPPL.VII): A18.
66. Sandborn, W.J., Hanauer, S., Enns, R., et al. (2005).Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study. Gut 54(Suppl.VII): A81-A82.
67. Scallon, B.J., Moore, M.A., Trinh, H., Knigh, D.M., Ghrayeb, J. (1995).Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259.
68. Schiff, M., van de Putte, L.B., Breedveld, F.C., et al. (2003)Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis 62(SUPPL.I): 184.
69. Schiff, M.H., Chartash, E., Spencer-Green, G. (2003).Malignancies in rheumatoid arthritis (RA) clinical trials with adalimumab (HUMIRA) [abstract]. Arthritis Rheum 48(9 Suppl.): S700.
70. Schiff, M.H., Weisman, M.H., Cohen, S.B., et al. (2004).Significant clinical improvement at 6 months are sustained over 4 years in patients with rheumatoid arthritis treated with adalimumab (Humir) plus methotrexate. Arthritis Rheum 50(Suppl.): S182-S183.
71. Schiff, M.H., Burmester, G.R., Kent, J., et al. (2005).Safety of adalimumab in long-term treatment of patients with rheumatoid arthritis [abstract]. J Am Acad Dermatol 52(3 Suppl.): 203.
72. Schiff, M.H., Breedveld, F.C., Weisman, M.H., et al. (2005).Adalimumab (Humir) plus methotrexate is safe and efficacious in patients with rheumatoid arthritis into the seventh year of therapy [abstract]. Ann Rheum Dis 64(Suppl. III): 438-439.
73. Schiff, M.H., Burmester, G.R., Kent, J.D., et al. (2006).Safety analyses of adalimumab (Humir) in global clinical trials with US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889-894.
74. Shen, C., Assche, G.V., Colpaert, S., et al. (2005).Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251-258.
75. Soden, M., Rooney, M., Cullen, A., Whelan, A., Feighery, C., Bresnihan, B. (1989).Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol 28: 287-292.
76. Stallmach, A., Giese, T., Schmidt, C., Meuer, S.C., Zeuzem, S.S. (2004).Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol 16: 627-630.
77. Tsakonas, E., Fitzgerald, A.A., Fitzcharles, M.A., et al. (2000).Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis HERA study. JRheumatol 27: 623-629.
78. Van Der Bijl, A.E., Breedveld, F.C., Antoni, C.E., et al. (2005).Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment. Ann Rheum Dis 64(Suppl.III): 428.
79. Van Den Brande, J.M., Braat, H., van den Brink, G.R., et al. (2003).Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785.
80. Van Der Heijde, D., Kivitz, A., Schiff, M.H., et al. for the Adalimumab Trial Evaluating Long-term Efficacy and Safety in Ankylosing Spondylitis Study Group (2006).Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum 54: 2136-2146.
81. Van De Putte, L.B.A., Salfeld, J., Kaymakcalan, Z. (2003)Adalimumab. In: Moreland, L.W. Emery, P. (Eds.), TNF-Inhibition in the Treatment of Rheumatoid Arthritis. Martin Dunitz, London, pp. 71-93
82. Van De Putte, L.B., Atkins, C., Malaise, M., et al. (2004).Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63: 508-516.
83. Wallace, K.L., Langley, R., Bissonnette, R., Melluli, L., Hoffman, R. (2005).Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis [abstract]. J Am Acad Dermatol 52(3Suppl.): 192.
84. Wallace, K.L., Gordon, K.B., Langley, M., et al. (2005).Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl.): 180.
85. Wallace, K.L., Bissonnette, R., Leonardi, C., et al. (2005).Effects of adalimumab on health status as measured by EQ-5D in patients with moderate to severe plaque psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl.): 181.
86. Wallace, K.L., Leonardi, C., Kempers, S., et al. (2005).General physical and mental health status in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl.): 185.
87. Weinblatt, M.E., Keystone, E.C., Furst, D.E., et al. (2003).Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48: 35-45.
88. Weinblatt, M.E., Keystone, E.C., Furst, D.E., Kavanaugh, A.F., Cartash, E.K., Segurado, O.G. (2005)Long-term efficacy, remission, and safety of adalimumab (HUMIRA) plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial [abstract].Arthritis Rheum 52 (SUPPL): 563.
89. Weinblatt, M.E., Keystone, E.C., Furst, D.E., Kavanaugh, A.F., Chartash, E.K., Segurado, O.G. (2006).Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 65: 753-759.
90. Wells, A.F., Kupper, H., Fischkoff, S., et al. (2003).Injection site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann Rheum Dis 62(Suppl.I): 411.
91. Williams, R.O., Feldmann, M., Miani, R.N. (1992).Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 974-978.
92. Youdim, A., Vasikiauskas, E.A., Targan, S.R., et al. (2004).A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10: 333-338.
93. Zhou, H., Buckwalter, M., Boni, J., et al. (2004).Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42: 267-276.